Sarojam Radhakrishnan from Kerala, diagnosed with breast cancer in 2021, couldn’t afford the ₹63,000/month treatment. So she sued. Her case reached the Supreme Court, where judges called drug markups ‘extortion’; some drugs were being sold at 700% above cost. The government just capped margins on 137 cancer drugs, slashing prices by up to 70% and saving patients ₹2,500 crore annually. This isn’t just about medicine; it’s about survival. Millions skip diagnosis because they can’t afford treatment. Ayushman Bharat covers only one dose of some drugs. Her fight sparked a system-wide rethink. And now, the court is asking: if we cap cancer drugs, why not all non-patented drugs? She lost her battle, but won a war for thousands after her.